Zhuhai Sailong Pharmaceutical Co Ltd - Asset Resilience Ratio
Zhuhai Sailong Pharmaceutical Co Ltd (002898) has an Asset Resilience Ratio of 1.19% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 002898 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how Zhuhai Sailong Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See what is Zhuhai Sailong Pharmaceutical Co Ltd's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Zhuhai Sailong Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002898 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥10.00 Million | 1.19% |
| Total Liquid Assets | CN¥10.00 Million | 1.19% |
Asset Resilience Insights
- Limited Liquidity: Zhuhai Sailong Pharmaceutical Co Ltd maintains only 1.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhuhai Sailong Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhuhai Sailong Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Zhuhai Sailong Pharmaceutical Co Ltd (2020–2023)
The table below shows the annual Asset Resilience Ratio data for Zhuhai Sailong Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.26% | CN¥2.14 Million ≈ $313.68K |
CN¥813.84 Million ≈ $119.09 Million |
+2.33pp |
| 2022-12-31 | -2.07% | CN¥-17.52 Million ≈ $-2.56 Million |
CN¥847.99 Million ≈ $124.09 Million |
-0.04pp |
| 2021-12-31 | -2.03% | CN¥-17.89 Million ≈ $-2.62 Million |
CN¥882.78 Million ≈ $129.18 Million |
-- |
| 2020-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥813.96 Million ≈ $119.11 Million |
-- |
About Zhuhai Sailong Pharmaceutical Co Ltd
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pan… Read more